The FDA extended its review of Exelixis' cancer drug zanzalintinib by three months without revealing any new clinical failures or safety concerns. This delay reduces the drug's present value by about 2.35%, which is less than the initial market loss. Exelixis' other drug, CABOMETYX, continues to grow, and the company's 2026 revenue guidance does not include zanzalintinib sales. The stock trades at a reasonable valuation, and the analyst maintains a Buy rating with a $68 price target.
Flutter Entertainment, a leading online sports betting and iGaming operator, will release its third quarter 2026 update on November 4 before the US market opens. The company will host a conference call at 8:30 a.m. ET the same day to discuss the resu...
iPower Inc. declared a 1-for-12 reverse stock split effective October 26, 2026, combining every 12 shares into one to increase the stock price. This move aims to keep iPower's shares compliant with Nasdaq's minimum bid price requirements. Post-split,...
U.S. Global Investors has listed its actively managed U.S. Global Technology and Aerospace & Defense ETF (WAR) on Peru's Lima Stock Exchange, marking the first availability of this ETF outside the U.S. This move gives Peruvian investors access to a f...
Alignment Health Plan will launch a new Medicare Advantage plan in Pima County starting January 1, 2027, increasing access to affordable, coordinated healthcare for nearly 1.1 million Medicare beneficiaries across Maricopa, Pima, and Santa Cruz count...
The global Urban Air Mobility (UAM) market is projected to grow from $2.16 billion in 2026 to $16.27 billion by 2035, at a CAGR of 20.9%. This growth is fueled by rising urbanization, traffic congestion, and advances in electric vertical takeoff and ...
